Open Payments

BOSTON MEDICAL CENTER

Type
Teaching hospital
Where
Boston, MA
Medicare CCN
220031
Received
$6,156,199 in 488 records, 2024 ($1,612,697 general, $4,543,501 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment71$1,612,697
2024Research payment417$4,543,501

By company

CompanyRecordsAmountYears
PFIZER INC.42$1,172,9782024
Genentech, Inc.4$781,3322024
Takeda Pharmaceuticals U.S.A., Inc.12$541,8182024
E.R. Squibb & Sons, L.L.C.4$443,3432024
VERTEX PHARMACEUTICALS INCORPORATED3$371,3632024
Novartis Pharmaceuticals Corporation1$268,2182024
Janssen Research & Development, LLC58$259,3862024
Eli Lilly and Company2$239,8542024
Zevra Therapeutics Inc1$236,6102024
Gilead Sciences, Inc.21$231,9992024
Deciphera Pharmaceuticals Inc.13$169,4562024
ConvaTec Inc.4$137,3512024
Otsuka Pharmaceutical Co., Ltd.1$134,4932024
Indivior Inc.18$129,9952024
Abbott Laboratories20$127,2322024
Alexion Pharmaceuticals, Inc.2$123,2482024
Tandem Diabetes Care, Inc.1$93,3272024
ABBVIE INC.13$66,0492024
GlaxoSmithKline, LLC.20$61,1662024
Bard Peripheral Vascular, Inc.5$52,8122024
ANI Pharmaceuticals, Inc.1$50,5362024
GLOBAL BLOOD THERAPEUTICS, INC.6$49,7172024
Acera Surgical, Inc.8$48,0932024
INSTYLLA, INC.5$42,4062024
Immedica Pharma US, Inc.5$37,4562024
Celgene Corporation2$34,4502024
Intercept Pharma Europe Ltd.3$33,0882024
Route 92 Medical, Inc.1$30,0612024
Madrigal Pharmaceuticals5$28,2922024
Novo Nordisk AS145$27,2192024
Mannkind Corporation3$21,7632024
KARL STORZ Endoscopy-America17$19,8332024
Boston Scientific Corporation2$15,1402024
KLS-Martin L.P.4$15,0002024
SANOFI US SERVICES INC.2$13,2432024
Theratechnologies Inc.3$13,0512024
Kaneka Medical America LLC1$11,9002024
Organon Llc4$5,2592024
Stryker Corporation2$4,4182024
Acrotech Biopharma Inc.2$3,8222024
Fisher Scientific Company L.L.C.8$1,6502024
Medical Device Business Services, Inc.2$1,5552024
Smith+Nephew, Inc.1$1,5002024
F. Hoffmann-La Roche AG1$1,3002024
CSL Behring1$1,3002024
National Marrow Donor Program3$1,0402024
Agios Pharmaceuticals, Inc.1$4552024
Regeneron Pharmaceuticals, Inc.1$4002024
AstraZeneca Pharmaceuticals LP2$752024
Catalent Pharma Solutions, LLC1$752024

By nature of payment

NatureRecordsAmount
Research payment417$4,543,501
Grant10$1,007,637
Charitable Contribution8$443,765
Compensation for services other than consulting, including serving as faculty or as a speaker at a v21$131,035
Education17$19,833
Long term medical supply or device loan6$7,274
Debt forgiveness8$1,650
Space rental or facility fees (teaching hospital only)1$1,500

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31Zevra Therapeutics Inc$236,610Research paymentIn-kind items and servicesMIPLYFFA Drug, Neurodegenerative DiseaseEarly Access Program With Arimoclomol in US Patients With NPC2024
2024-12-31KARL STORZ Endoscopy-America$7,244EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31Janssen Research & Development, LLC$3,900Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-31KARL STORZ Endoscopy-America$2,591EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31Stryker Corporation$2,209Long term medical supply or device loanIn-kind items and servicesCORE Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$2,209Long term medical supply or device loanIn-kind items and servicesCORE Device, INSTRUMENTS2024
2024-12-31KARL STORZ Endoscopy-America$2,039EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31KARL STORZ Endoscopy-America$2,039EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31ABBVIE INC.$1,166Research paymentIn-kind items and servicesM16-077 Elezanumab Ph 2a POC SCI ELASCI2024
2024-12-31KARL STORZ Endoscopy-America$880EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31KARL STORZ Endoscopy-America$730EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31KARL STORZ Endoscopy-America$730EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31KARL STORZ Endoscopy-America$730EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31KARL STORZ Endoscopy-America$730EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31Janssen Research & Development, LLC$492Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-31KARL STORZ Endoscopy-America$423EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31KARL STORZ Endoscopy-America$283EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31KARL STORZ Endoscopy-America$213EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31KARL STORZ Endoscopy-America$186EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31KARL STORZ Endoscopy-America$154EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31KARL STORZ Endoscopy-America$136EducationIn-kind items and servicesTELE PACK Device, VIDEOIMAGING2024
2024-12-31Teleflex LLC$55Long term medical supply or device loanIn-kind items and servicesWECK Device, SURGICAL2024
2024-12-26Madrigal Pharmaceuticals$2,414Research paymentCash or cash equivalentA 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmet2024
2024-12-26Madrigal Pharmaceuticals$195Research paymentCash or cash equivalentA 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmet2024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Janssen Research & Development, LLC$1,303Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-12-23Gilead Sciences, Inc.$195Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-12-23Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522024
2024-12-20Janssen Research & Development, LLC$5,257Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2024
2024-12-20Novo Nordisk AS$2,146Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-12-20Novo Nordisk AS$487Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-12-20Novo Nordisk AS$250Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-12-19Janssen Research & Development, LLC$4,355Research paymentCash or cash equivalentA Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced 2024
2024-12-19Janssen Research & Development, LLC$1,148Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car2024
2024-12-17Gilead Sciences, Inc.$74,913GrantCash or cash equivalent2024
2024-12-17Gilead Sciences, Inc.$1,671Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-12-13Janssen Research & Development, LLC$20,453Research paymentCash or cash equivalentA Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced 2024
2024-12-13Janssen Research & Development, LLC$4,272Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car2024
2024-12-11Takeda Pharmaceuticals U.S.A., Inc.$195Research paymentCash or cash equivalentSTUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI2024
2024-12-10ANI Pharmaceuticals, Inc.$50,536Research paymentCash or cash equivalentPURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RAStudy of the potential therapeutic use of Purified Cortrophin Gel for uveitis2024
2024-12-10PFIZER INC.$2,792Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-12-09PFIZER INC.$226,180Research paymentCash or cash equivalentSURVEILLANCE OF PNEUMOCOCCAL COLONIZATION IN CHILDREN LESS THAN 5 YEARS OF AGE AT BOSTON MEDICAL CENTER2024
2024-12-07AstraZeneca Pharmaceuticals LP$50Charitable ContributionCash or cash equivalent2024
2024-12-06Indivior Inc.$9,996Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-12-06Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-12-05ABBVIE INC.$4,466Research paymentCash or cash equivalentA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch2024
2024-12-05ABBVIE INC.$1,911Research paymentCash or cash equivalentSafety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco2024
2024-12-05Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522024
2024-12-02Takeda Pharmaceuticals U.S.A., Inc.$17,725Research paymentCash or cash equivalentPOST-OP RECOVERY - OREXIN2024
2024-12-02Kaneka Medical America LLC$11,900Research paymentCash or cash equivalentKEEP Study2024
2024-12-02Takeda Pharmaceuticals U.S.A., Inc.$3,900Research paymentCash or cash equivalentPOST-OP RECOVERY - OREXIN2024
2024-12-02Abbott Laboratories$218Research paymentIn-kind items and servicesFREESTYLE LIBRE 2 Device, DIABETES CAREJANUS 12024
2024-12-01Theratechnologies Inc.$250Research paymentCash or cash equivalentTROGARZO Drug, HIVA Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab 2024
2024-11-28Janssen Research & Development, LLC$2,296Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car2024
2024-11-27Madrigal Pharmaceuticals$14,704Research paymentCash or cash equivalentA 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmet2024
2024-11-27PFIZER INC.$9,309Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-11-25Janssen Research & Development, LLC$3,270Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2024
2024-11-25PFIZER INC.$252Research paymentCash or cash equivalentMEASURING PODOCYTE URINARY BIOMARKERS ACROSS RENAL DISORDERS2024
2024-11-25Gilead Sciences, Inc.$195Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-11-22Genentech, Inc.$749,509GrantCash or cash equivalent2024
2024-11-20Novo Nordisk AS$426Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-11-20Novo Nordisk AS$50Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-11-15Organon Llc$2,459Research paymentCash or cash equivalent8415-0602024
2024-11-14Medical Device Business Services, Inc.$1,230Research paymentCash or cash equivalentACTIS Device, Ortho-HipActis Total Hip System 2 Year Follow up2024
2024-11-14Madrigal Pharmaceuticals$195Research paymentCash or cash equivalentA 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmet2024
2024-11-13Takeda Pharmaceuticals U.S.A., Inc.$13,138Research paymentCash or cash equivalentSTUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI2024
2024-11-08Indivior Inc.$9,998Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-11-08Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-11-08GlaxoSmithKline, LLC.$108Research paymentCash or cash equivalentA PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE2024
2024-11-07ABBVIE INC.$21,394Research paymentCash or cash equivalentAn Open-Label Phase 1b Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis2024
2024-11-06Celgene Corporation$17,225Research paymentCash or cash equivalentExpanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commer2024
2024-11-06KLS-Martin L.P.$3,750GrantCash or cash equivalent2024
2024-11-05Gilead Sciences, Inc.$293Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-11-04E.R. Squibb & Sons, L.L.C.$21,275Research paymentCash or cash equivalentCOBENFY Drug, Psychiatry/PsychologyPhase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1)2024
2024-11-01Janssen Research & Development, LLC$6,307Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2024
2024-11-01Theratechnologies Inc.$3,194Research paymentCash or cash equivalentTROGARZO Drug, HIVA Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab 2024
2024-11-01Mannkind Corporation$2,015Research paymentCash or cash equivalentAFREZZA Drug, DIABETES MEDICINEINHALE-32024
2024-10-31ABBVIE INC.$11,575Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch2024
2024-10-31Novo Nordisk AS$2,438Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-10-31Novo Nordisk AS$125Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-10-30Deciphera Pharmaceuticals Inc.$69,975Research paymentIn-kind items and servicesQINLOCK Drug, ONCOLOGYA STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GIST WITH SPECIFIC KIT EXON MUTATIONS WHO WERE PREVIOUSLY T2024
2024-10-26PFIZER INC.$6,622Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-10-25Janssen Research & Development, LLC$2,490Research paymentCash or cash equivalentA Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced 2024
2024-10-25National Marrow Donor Program$475Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-10-22Gilead Sciences, Inc.$1,768Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-10-18Janssen Research & Development, LLC$1,640Research paymentCash or cash equivalentDARZALEX Drug, Oncology54767414AMY20092024
2024-10-17Boston Scientific Corporation$15,000Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN_ICRacial and Ethnic Inequities in Utilization of the Watchman Left Atrial Occlusion Device2024
2024-10-16PFIZER INC.$523Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-10-14Abbott Laboratories$215Research paymentIn-kind items and servicesFREESTYLE LIBRE 2 Device, DIABETES CAREJanus 12024
2024-10-14Abbott Laboratories$45Research paymentIn-kind items and servicesFREESTYLE LIBRE 2 Device, DIABETES CAREJanus 12024
2024-10-14Abbott Laboratories$35Research paymentIn-kind items and servicesFREESTYLE LIBRE 2 Device, DIABETES CAREJanus 12024
2024-10-14Abbott Laboratories$12Research paymentIn-kind items and servicesFREESTYLE LIBRE 2 Device, DIABETES CAREJanus 12024
2024-10-14Abbott Laboratories$10Research paymentIn-kind items and servicesFREESTYLE LIBRE 2 Device, DIABETES CAREJanus 12024
2024-10-11Indivior Inc.$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-10-11Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-10-11CSL Behring$1,300Research paymentCash or cash equivalentKcentra Biological, Trauma (Emergency, Injury, Surgery)A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1112024
2024-10-10Abbott Laboratories$11,328Research paymentIn-kind items and servicesFREESTYLE LIBRE 2 Device, DIABETES CAREJanus 12024
2024-10-10Abbott Laboratories$852Research paymentIn-kind items and servicesFREESTYLE LIBRE 2 Device, DIABETES CAREJanus 12024
2024-10-10Abbott Laboratories$218Research paymentIn-kind items and servicesFREESTYLE LIBRE 2 Device, DIABETES CAREJanus 12024
2024-10-09Takeda Pharmaceuticals U.S.A., Inc.$20,416Research paymentCash or cash equivalentHEPATIC IMPAIRMENT2024
2024-10-09Takeda Pharmaceuticals U.S.A., Inc.$5,392Research paymentCash or cash equivalentHEPATIC IMPAIRMENT2024
2024-10-09Takeda Pharmaceuticals U.S.A., Inc.$3,900Research paymentCash or cash equivalentHEPATIC IMPAIRMENT2024
2024-10-09INSTYLLA, INC.$3,475Research paymentCash or cash equivalentVERGE MICROCATHETER Device, Liquid Embolics for Interventional RadiologyRandomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of2024
2024-10-08Abbott Laboratories$7,250Research paymentCash or cash equivalentFreeStyle Libre 2 Device, DIABETES CAREJanus 12024
2024-10-07Janssen Research & Development, LLC$4,355Research paymentCash or cash equivalentA Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced 2024
2024-10-04GlaxoSmithKline, LLC.$4,237Research paymentCash or cash equivalentA PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE2024
2024-10-03PFIZER INC.$227Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-09-30Janssen Research & Development, LLC$2,136Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car2024
2024-09-30Organon Llc$1,400Long term medical supply or device loanIn-kind items and servicesJADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING2024
2024-09-29KARL STORZ Endoscopy-America$44EducationIn-kind items and services2024
2024-09-26Madrigal Pharmaceuticals$10,782Research paymentCash or cash equivalentRESMETIROM Drug, LIVER DISEASEA 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmet2024
2024-09-26Janssen Research & Development, LLC$1,427Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2024
2024-09-26KARL STORZ Endoscopy-America$675EducationIn-kind items and servicesCLICKLINE Device, LAPAROSCOPY2024
2024-09-25Bard Peripheral Vascular, Inc.$7,719Research paymentCash or cash equivalentLutonix AV PAS2024
2024-09-24Gilead Sciences, Inc.$195Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-09-20Janssen Research & Development, LLC$14,615Research paymentCash or cash equivalentA Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced 2024
2024-09-20GlaxoSmithKline, LLC.$2,347Research paymentCash or cash equivalentA PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE2024
2024-09-20Novo Nordisk AS$1,743Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-09-20Janssen Research & Development, LLC$519Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2024
2024-09-20Novo Nordisk AS$250Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-09-19ABBVIE INC.$1,300Research paymentCash or cash equivalentSafety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco2024
2024-09-18PFIZER INC.$487Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2024
2024-09-17ABBVIE INC.$2,599Research paymentCash or cash equivalentSafety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco2024
2024-09-16ABBVIE INC.$16,900Research paymentCash or cash equivalentA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch2024
2024-09-12ABBVIE INC.$325Research paymentCash or cash equivalentSafety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco2024
2024-09-06Indivior Inc.$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-09-06Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-09-04PFIZER INC.$1,560Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-09-04GlaxoSmithKline, LLC.$162Research paymentCash or cash equivalentA PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E2024
2024-09-04GlaxoSmithKline, LLC.$162Research paymentCash or cash equivalentA PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E2024
2024-09-04GlaxoSmithKline, LLC.$162Research paymentCash or cash equivalentA PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E2024
2024-09-03PFIZER INC.$49,815Research paymentCash or cash equivalentSURVEILLANCE OF PNEUMOCOCCAL COLONIZATION IN CHILDREN LESS THAN 5 YEARS OF AGE AT BOSTON MEDICAL CENTER2024
2024-09-03Takeda Pharmaceuticals U.S.A., Inc.$2,050Research paymentCash or cash equivalentSTUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI2024
2024-08-30Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522024
2024-08-29Janssen Research & Development, LLC$238Research paymentCash or cash equivalentDARZALEX Drug, OncologyRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2024
2024-08-27Bard Peripheral Vascular, Inc.$20,629Research paymentCash or cash equivalentAGILITY BDPI-20-0102024
2024-08-27Gilead Sciences, Inc.$10,000GrantCash or cash equivalent2024
2024-08-27Janssen Research & Development, LLC$2,764Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2024
2024-08-27Gilead Sciences, Inc.$2,245Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-08-27VERTEX PHARMACEUTICALS INCORPORATED$1,911Research paymentCash or cash equivalentA Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are2024
2024-08-23Takeda Pharmaceuticals U.S.A., Inc.$220,000Charitable ContributionCash or cash equivalent2024
2024-08-23Takeda Pharmaceuticals U.S.A., Inc.$220,000Charitable ContributionCash or cash equivalent2024
2024-08-23Fisher Scientific Company L.L.C.$114Debt forgivenessCash or cash equivalent2024
2024-08-23Fisher Scientific Company L.L.C.$35Debt forgivenessCash or cash equivalent2024
2024-08-23Fisher Scientific Company L.L.C.$20Debt forgivenessCash or cash equivalent2024
2024-08-22Janssen Research & Development, LLC$5,411Research paymentCash or cash equivalentA Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced 2024
2024-08-21Gilead Sciences, Inc.$2,685Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-08-20Gilead Sciences, Inc.$293Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-08-15Janssen Research & Development, LLC$4,926Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2024
2024-08-15INSTYLLA, INC.$1,800Research paymentCash or cash equivalentVERGE MICROCATHETER Device, Liquid Embolics for Interventional RadiologyRandomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of2024
2024-08-14ConvaTec Inc.$1,300Research paymentCash or cash equivalentAQUACEL FOAM Device, ADVANCED WOUND CAREA Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance a2024
2024-08-09Indivior Inc.$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-08-09Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-08-08PFIZER INC.$78,780Research paymentCash or cash equivalentDEVELOPING NEUTRALIZING SLIT23 MAB FOR TREATMENT OF GLOMERU2024
2024-08-02GlaxoSmithKline, LLC.$21,079Research paymentCash or cash equivalentA PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE2024
2024-08-01Abbott Laboratories$13,511Research paymentCash or cash equivalentFREESTYLE LIBRE Device, DIABETES CAREEvaluation of Flash Continuous Glucose Monitoring to Reduce Hypergycemia in People with T2 Diabetes2024
2024-08-01PFIZER INC.$860Research paymentCash or cash equivalentMEASURING PODOCYTE URINARY BIOMARKERS ACROSS RENAL DISORDERS2024
2024-07-31GLOBAL BLOOD THERAPEUTICS, INC.$2,082Research paymentCash or cash equivalentOXBRYTA Drug, HEMATOLOGYAN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXEL2024
2024-07-31INSTYLLA, INC.$2,050Research paymentCash or cash equivalentVERGE MICROCATHETER Device, Liquid Embolics for Interventional RadiologyA PROSPECTIVE, NON-RANDOMIZED SINGLE-ARM PILOT STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF INSTYLLA HES FOR TRANSCAT2024
2024-07-29Janssen Research & Development, LLC$6,991Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car2024
2024-07-29Janssen Research & Development, LLC$4,737Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car2024
2024-07-29PFIZER INC.$1,403Research paymentCash or cash equivalentMEASURING PODOCYTE URINARY BIOMARKERS ACROSS RENAL DISORDERS2024
2024-07-25Janssen Research & Development, LLC$7,378Research paymentCash or cash equivalentA Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced 2024
2024-07-25PFIZER INC.$2,136Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-07-22Novo Nordisk AS$3,172Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-07-22Novo Nordisk AS$250Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-07-17KLS-Martin L.P.$3,750GrantCash or cash equivalent2024
2024-07-16Gilead Sciences, Inc.$3,206Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-07-16Gilead Sciences, Inc.$195Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-07-12GlaxoSmithKline, LLC.$162Research paymentCash or cash equivalentA PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E2024
2024-07-10ConvaTec Inc.$1,300Research paymentCash or cash equivalentAQUACEL FOAM Device, ADVANCED WOUND CAREA Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance a2024
2024-07-09Gilead Sciences, Inc.$56,058GrantCash or cash equivalent2024
2024-07-09Gilead Sciences, Inc.$293Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB2024
2024-07-01Janssen Research & Development, LLC$5,447Research paymentCash or cash equivalentA Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced 2024
2024-07-01PFIZER INC.$4,818Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESSURVEILLANCE OF PNEUMOCOCCAL COLONIZATION IN CHILDREN LESS THAN 5 YEARS OF AGE AT BOSTON MEDICAL CENTER2024
2024-06-29PFIZER INC.$34,595Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-06-28Indivior Inc.$10,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-06-28Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2024
2024-06-27PFIZER INC.$10,875Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2024
2024-06-27Janssen Research & Development, LLC$7,800Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car2024
2024-06-25Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522024
2024-06-21ConvaTec Inc.$2,600Research paymentCash or cash equivalentAQUACEL FOAM Device, ADVANCED WOUND CAREA Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance a2024
2024-06-21Novo Nordisk AS$1,586Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-06-21Organon Llc$700Long term medical supply or device loanIn-kind items and servicesJADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING2024
2024-06-21Novo Nordisk AS$375Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-06-20Janssen Research & Development, LLC$2,894Research paymentCash or cash equivalentCARVYKTI Drug, OncologyIntermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specificatio2024
2024-06-19PFIZER INC.$6,213Research paymentCash or cash equivalentPAXLOVID Drug, INFECTIOUS DISEASESA PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL2024
2024-06-14E.R. Squibb & Sons, L.L.C.$45,722Research paymentCash or cash equivalentZEPOSIA Drug, NeurosciencePhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202)2024
2024-06-14GlaxoSmithKline, LLC.$873Research paymentCash or cash equivalentA PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE2024
2024-06-13Janssen Research & Development, LLC$13,929Research paymentCash or cash equivalentA Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu2024

The latest 200 records of 488.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Suffolk CountyBoston city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.

MeasurePlace (city or town)
Boston, MA
County
Suffolk County, MA
State
Massachusetts
Population B01003666,442785,1217,044,056
Population, 2020 census P1675,647797,9367,029,917
Median age B0100233.333.940.0
Under 18 B0100115.1%16.0%19.4%
65 and over B0100113.0%13.3%17.9%
Households B11001283,374327,1672,785,042
Foreign born B0500227.8%29.8%18.0%
Median household income B19013$97,344$95,631$103,960
Median family income B19113$116,436$112,072$131,675
Per capita income B19301$61,698$58,636$57,897
Poverty rate B1700116.6%16.2%10.0%
Unemployment rate B230256.1%6.3%5.2%
Civilian labor force B23025402,354468,6363,911,446
Mean commute (minutes) B0801330.330.929.1
Bachelor's degree or higher B1500354.9%50.6%47.3%
Housing units B25001310,625357,2903,030,406
Owner-occupied B2500335.7%36.5%62.5%
Renters B2500364.3%63.5%37.5%
Median home value B25077$731,700$705,800$562,100
Median gross rent B25064$2,147$2,129$1,762
White, not Hispanic B0300244.1%43.6%66.6%
Black B0300219.3%17.1%6.4%
Hispanic or Latino B0300219.3%23.2%13.3%
Asian B0300210.3%9.2%7.3%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.